AstraZeneca Opens New US$37.8 (£26) Million Tablets Expansion Facility
 Back
|
|
AstraZeneca opened a new US$ 37.8 million tablets expansion facility at its manufacturing site in Macclesfield, Cheshire, to provide further launch and growth capacity for treatments for serious medical disorders. One of its initial roles is in the manufacture of 'Seroquel' (quetiapine), for the treatment of schizophrenia.
The facility will double previous granulation capacity for tablet formulations produced at Macclesfield, which is AstraZeneca's second largest manufacturing site worldwide. Twenty new employees have joined the existing workforce to operate the new facility.
The tablets expansion facility will source many products across various disease areas, including major treatments soon to be launched for international markets.
The investment in the new tablets facility is part of an extensive range of projects which are being carried out to meet business demands. Major refurbishment and remodelling of production facilities has been carried out at Macclesfield in a short timescale to ensure the site has the capacity to meet ambitious growth targets for various products. Other projects which are part of the major investment programme at Macclesfield, totalling US$ 112 million (77 million GBP), include new packaging facilities for several other significant products in the AstraZeneca portfolio. In total, almost twenty projects are involved in the programme, which has been completed five months ahead of schedule, thanks to effective cross-functional teamwork.
|
|
|
Suppliers that worked on this project
|
|
|
| Fast Facts
|
Cost:
$37,800,000 |
|
Size:
Not Available |
|
|
Location: Macclesfield, Cheshire, UK |
|
|
|
| |